Skip to content

Clinical trials

Borderline Personality Disorder trials in Germany

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Borderline Personality Disorder Country / region: Germany Clear all

37 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20042
20051
20091
20111
20121
20142
20151
20163
20172
20181
20192
20205
20214
20222
20231
20244
20252
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed24
Unknown status6
Recruiting4
Terminated2
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Central Institute of Mental Health, Mannheim4
Charite University, Berlin, Germany4
Evangelisches Krankenhaus Bielefeld gGmbH3
Boehringer Ingelheim2
Gaia AG2
Heidelberg University2
Katharina Bachmann2
University of Oldenburg2
Christian Paret1
Eli Lilly and Company1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Borderline Personality Disorder37
Stress Disorders, Post-Traumatic5
Attention Deficit Disorder with Hyperactivity3
Personality Disorders3
Dissociative Disorders2
Anxiety Disorders1
Compulsive Personality Disorder1
Feeding and Eating Disorders1
Major Depressive Disorder1
Mental Disorders1

Trials

Showing 51 to 37 of 37. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.